<DOC>
	<DOCNO>NCT01043380</DOCNO>
	<brief_summary>The purpose study evaluate difference effect coronary plaque regression ( measure intravascular ultrasound [ IVUS ] image ) cholesterol absorption inhibitor cholesterol synthesis inhibitor .</brief_summary>
	<brief_title>Plaque REgression With Cholesterol Absorption Inhibitor Synthesis Inhibitor Evaluated IntraVascular UltraSound</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Signed write informed consent , 30 85 year old , Plan undergo PCI LDLC &gt; = 100 mg/dL Familial hypercholesterolemia Being treat Zetia ( Ezetimibe ) Being treat Fibrates Renal insufficiency ( serum creatinine &gt; = 2.0 mg/dl ) Altered hepatic function ( serum aspartate aminotransferase alanine aminotransferase &gt; = 3folds standard value institute ) Undergoing hemodialysis peritoneal dialysis Allergic Lipitor and/or Zetia Severe underlie disease Lack decisionmaking capacity Recognized inadequate attending doctor</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Heart Diseases</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Intravascular Ultrasound</keyword>
</DOC>